i
Plasma and Urine Biomarkers in Chronic Kidney Disease: Closer to Clinical Application
-
11 2021
Source: Curr Opin Nephrol Hypertens. 30(6):531-537 -
Alternative Title:Curr Opin Nephrol Hypertens
-
Publisher's site:
-
Personal Author:
-
Description:PURPOSE OF REVIEW
Chronic kidney disease (CKD) is a silent disease, causing significant health and economic burden worldwide. It is of strong clinical value to identify novel prognostic, predictive, and pharmacodynamic biomarkers of kidney function as current available measures have limitations. We reviewed the advances in biomarkers in CKD over the preceding year.
RECENT FINDINGS
The most frequently studied prognostic plasma biomarkers during recent year were plasma TNFR1, TNFR2, KIM1, and urinary MCP-1 and EGF. New biomarkers such as plasma WFDC2, MMP-7, EFNA4, EPHA2 may also have potential to serve as prognostic biomarkers. There is a shortage of data on biomarkers that are predictive of response to treatments. Data on novel biomarkers to serve as pharmacodynamic biomarkers are limited, but there is emerging data that plasmaTNFR1, TNFR2, KIM-1 are not only prognostic at baseline, but can contribute to time-updated response signals in response to therapy.
SUMMARY
Data continue to emerge on applicable biomarkers for prognostic clinical risk stratification, prediction of therapeutic response, and assessment of early efficacy of interventions. While more studies are needed for refinement and specific clinical utility, there seems to be sufficient data to support clinical implementation for some biomarkers.
-
Subject:
-
Pubmed ID:34475336
-
Pubmed Central ID:PMC8490303
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
File Type: